During closing arguments in the latest trial over the safety of Xarelto, Wilkinson Walsh + Eskovitz attorney Brian Stekloff, who argued for the defendant drugmakers, did not dispute that the blood thinner can cause severe and sometimes fatal bleeding, especially when combined with other anticoagulant medications.

But even acknowledging those risks, he stressed the treatment is necessary for patients with very complicated medical problems that are difficult to manage in closing arguments to a Philadelphia jury Tuesday.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]